<div id="readability-page-1">Medical device maker Abbott Laboratories (NYSE: ABT) on Thursday reported a 4% increase in sales for the fourth quarter of FY25. The company also issued its full-year 2026 guidance. <img src="https://imageproxy.pbkrs.com/https://cdn.news.alphastreet.com/wp-content/uploads/2026/01/Abbott-Laboratories-Q4-2025-Earnings.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1280" height="700" original-src="https://imageproxy.pbkrs.com/https://cdn.news.alphastreet.com/wp-content/uploads/2026/01/Abbott-Laboratories-Q4-2025-Earnings.jpg"/> Sales increased 4.4% year-over-year to $11.46 billion in the fourth quarter, with a 3% growth in organic sales. For fiscal 2026, Abbott expects organic sales growth to be in the range of 6.5% to 7.5%. Excluding special items, net earnings rose to $1.50 per share in the December quarter from $1.34 per share in the prior-year quarter. The company projects full-year adjusted earnings in the range of $5.55 per share to $5.80 per share, which reflects 10% growth at the midpoint On a reported basis, net income was $1.78 billion or $1.01 per share in the fourth quarter, vs. $9.2 billion or $5.27 per share in Q4 2024. “In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future,” said Robert Ford, Abbott’s CEO.The post Earnings: Highlights of Abbott Laboratories’ (ABT) Q4 2025 report first appeared on AlphaStreet.</div>

Abbott Laboratories (NYSE: ABT) reported a 4% increase in Q4 FY25 sales, reaching $11.46 billion, with organic sales growth of 3%. The company expects 6.5% to 7.5% organic sales growth for FY26. Net earnings rose to $1.50 per share, up from $1.34 per share year-over-year. Projected adjusted earnings for FY26 are between $5.55 and $5.80 per share, reflecting 10% growth at the midpoint. CEO Robert Ford highlighted margin expansion and a productive product pipeline in 2025.

Alpha Street

SPDR S&P Health Equip

Abbott Laboratories

Health Care Select Sector SPDR